Advanced Lung Cancer Inflammation Index is a Prognostic Factor of Patients with Small-Cell Lung Cancer Following Surgical Resection

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.26808342
   PubMed Web of Science ®Google Scholar
• Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664–672.25336398
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–1755. doi:10.1016/S0140-6736(11)60165-721565397
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3. 1973;4(2):31–42.
   PubMedGoogle Scholar
• Zhou T, Hong S, Hu Z, et al. A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumour Biol. 2015;36(1):337–343. doi:10.1007/s13277-014-2623-425256672
   PubMedGoogle Scholar
• Fruh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi99–105. doi:10.1093/annonc/mdt17823813929
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.00322995477
   PubMed Web of Science ®Google Scholar
• Grange JM, Krone B, Mastrangelo G. Infection, inflammation and cancer. Int J Cancer. 2011;128(9):2240–2241. doi:10.1002/ijc.2553320602341
   PubMed Web of Science ®Google Scholar
• Tomita M, Shimizu T, Ayabe T, et al. Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res. 2012;32(8):3535–3538.22843942
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer: a Glasgow inflammation outcome Study. Eur J Cancer. 2011;47(17):2633–2641. doi:10.1016/j.ejca.2011.03.02821724383
   PubMed Web of Science ®Google Scholar
• Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13(1):158. doi:10.1186/1471-2407-13-15823530866
   PubMed Web of Science ®Google Scholar
• He X, Zhou T, Yang Y, et al. Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin Lung Cancer. 2015;16(6):e165–171. doi:10.1016/j.cllc.2015.03.00525922292
   PubMed Web of Science ®Google Scholar
• Feng JF, Huang Y, Chen QX. A new inflammation index is useful for patients with esophageal squamous cell carcinoma. Onco Targets Ther. 2014;7:1811–1815. doi:10.2147/OTT.S6808425336972
   PubMed Web of Science ®Google Scholar
• Park YH, Yi HG, Lee MH, et al. Prognostic value of the pretreatment advanced lung cancer inflammation index (ALI) in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Acta Haematol. 2017;137(2):76–85. doi:10.1159/00045299128076862
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-011229684
   PubMed Web of Science ®Google Scholar
• Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7(3):211–217. doi:10.1016/j.ccr.2005.02.01315766659
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang L, Liu WX, et al. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in Chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev. 2015;16(3):933–939. doi:10.7314/APJCP.2015.16.3.93325735385
   PubMedGoogle Scholar
• Zhao QT, Yang Y, Xu S, et al. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7054 patients. Onco Targets Ther. 2015;8:2731–2738. doi:10.2147/OTT.S9087526491346
   PubMed Web of Science ®Google Scholar
• Charles KA, Harris BD, Haddad CR, et al. Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients. BMC Cancer. 2016;16(1):124. doi:10.1186/s12885-016-2089-426892430
   PubMed Web of Science ®Google Scholar
• Sekine K, Kanda S, Goto Y, et al. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer. 2018;124:179–188. doi:10.1016/j.lungcan.2018.08.01230268458
   PubMed Web of Science ®Google Scholar
• Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res. 2015;2015:983698. doi:10.1155/2015/98369826819959
   PubMed Web of Science ®Google Scholar
• Wang Q, Li Z, Sun L, et al. Platelets enhance the ability of bone-marrow mesenchymal stem cells to promote cancer metastasis. Onco Targets Ther. 2018;11:8251–8263. doi:10.2147/OTT.S18167330538494
   PubMed Web of Science ®Google Scholar
• Kono SA, Heasley LE, Doebele RC, et al. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets. 2012;12(2):107–123. doi:10.2174/15680091279909514422165970
   PubMed Web of Science ®Google Scholar
• Valero C, Pardo L, Lopez M, et al. Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer. Head Neck. 2017;39(2):219–226. doi:10.1002/hed.2456127534525
   PubMed Web of Science ®Google Scholar
• Eerola AK, Soini Y, Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res. 2000;6(5):1875–1881.10815910
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94(2):275–280. doi:10.1038/sj.bjc.660293416421594
   PubMed Web of Science ®Google Scholar
• Peng LS, Zhang JY, Teng YS, et al. Tumor-associated monocytes/macrophages impair NK-cell function via TGFbeta1 in human gastric cancer. Cancer Immunol Res. 2017;5(3):248–256. doi:10.1158/2326-6066.CIR-16-015228148545
   PubMed Web of Science ®Google Scholar
• Wang YQ, Zhu YJ, Pan JH, et al. Peripheral monocyte count: an independent diagnostic and prognostic biomarker for prostate cancer - a large Chinese cohort study. Asian J Androl. 2017;19(5):579–585. doi:10.4103/1008-682X.18618527569002
   PubMed Web of Science ®Google Scholar
• Han L, Jia Y, Song Q, et al. Prognostic significance of preoperative absolute peripheral monocyte count in esophageal squamous cell carcinoma. Dis Esophagus. 2016;29(7):740–746. doi:10.1111/dote.1240126316375
   PubMed Web of Science ®Google Scholar
• Kim EY, Lee JW, Yoo HM, et al. The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in gastric cancer? Ann Surg Oncol. 2015;22(13):4363–4370. doi:10.1245/s10434-015-4518-z25805235
   PubMed Web of Science ®Google Scholar
• Shao N, Cai Q. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer. Clin Transl Oncol. 2015;17(10):772–778. doi:10.1007/s12094-015-1289-826243392
   PubMed Web of Science ®Google Scholar
• Hirahara N, Matsubara T, Kawahara D, et al. Prognostic significance of preoperative inflammatory response biomarkers in patients undergoing curative thoracoscopic esophagectomy for esophageal squamous cell carcinoma. Eur J Surg Oncol. 2017;43(2):493–501. doi:10.1016/j.ejso.2016.11.01828034501
   PubMed Web of Science ®Google Scholar
• Pan YC, Jia ZF, Cao DH, et al. Preoperative lymphocyte-to-monocyte ratio (LMR) could independently predict overall survival of resectable gastric cancer patients. Medicine (Baltimore). 2018;97(52):e13896. doi:10.1097/MD.000000000001389630593200
   PubMed Web of Science ®Google Scholar
• Costello R, O’Callaghan T, Sébahoum G. Eosinophils and antitumour response. Rev Med Interne. 2005;26(6):479–484. doi:10.1016/j.revmed.2005.02.01315908052
   PubMed Web of Science ®Google Scholar
• Dellon AL, Hume RB, Chretien PB. Eosinophilia in bronchogenic carcinoma. N Eng lJ Med. 1974;291:207–208.
   PubMedGoogle Scholar
• Divack DM, Janovski NA. Eosinophilia encountered in female genital organs. Am J Obstet Gynecol. 1962;84(6):761–763. doi:10.1016/0002-9378(62)90028-513886615
   PubMed Web of Science ®Google Scholar
• De Monte L, Wörmann S, Brunetto E, et al. Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients. Cancer Res. 2016;76(7):1792–1803. doi:10.1158/0008-5472.CAN-15-1801-T26873846
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi:10.1016/S1470-2045(10)70218-721296615
   PubMed Web of Science ®Google Scholar
• McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–262. doi:10.1017/S002966510800713118452641
   PubMed Web of Science ®Google Scholar
• Jin Y, Zhao L, Peng F. Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer. Clinics (Sao Paulo). 2013;68(5):686–693. doi:10.6061/clinics/2013(05)1723778417
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Toyazaki T, Chiba N, et al. Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. Interact Cardiovasc Surg. 2016;23(4):560–566. doi:10.1093/icvts/ivw175
   PubMed Web of Science ®Google Scholar
• Tewari N, Martin-Ucar AE, Black E, et al. Nutritional status affects long term survival after lobectomy for lung cancer. Lung Cancer. 2007;57(3):389–394. doi:10.1016/j.lungcan.2007.03.01717481775
   PubMed Web of Science ®Google Scholar
• Tomita M, Ayabe T, Chosa E, et al. Prognostic significance of pre- and postoperative Glasgow prognostic score for patients with non small cell lung cancer. Anticancer Res. 2014;34(6):3137–3140.24922684
   PubMed Web of Science ®Google Scholar
• Yotsukura M, Ohtsuka T, Kaseda K, et al. Value of the Glasgow prognostic score as a prognostic factor in resectable non-small cell lung cancer. J Thorac Oncol. 2016;11(8):1311–1318. doi:10.1016/j.jtho.2016.04.02927234603
   PubMed Web of Science ®Google Scholar
• Kim EY, Kim N, Kim YS, et al. Prognostic significance of modified advanced lung cancer inflammation index (ALI) in patients with small cell lung cancer – comparison with original ALI. PLoS One. 2016;11(10):e0164056. doi:10.1371/journal.pone.016405627706243
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhao Y, Zhao S, et al. Comparison of the prognostic value of systemic inflammation response markers in small cell lung cancer patients. J Cancer. 2019;10(7):1685–1692. doi:10.7150/jca.2931931205524
   PubMed Web of Science ®Google Scholar
• Tomita M, Ayabe T, Nakamura K. The advanced lung cancer inflammation index is an independent prognostic factor after surgical resection in patients with nonsmall-cell lung cancer. Interact Cardiovasc Thorac Surg. 2018;26(2):288–292. doi:10.1093/icvts/ivx32929049691
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Karube Y, Inoue T, et al. Advanced lung cancer inflammation index predicts outcomes of patients with pathological stage IA lung adenocarcinoma following surgical resection. Ann Thorac Cardiovasc Surg. 2019;25(2):87–94. doi:10.5761/atcs.oa.18-0015830333361
   PubMed Web of Science ®Google Scholar
• Combs SE, Hancock JG, Boffa DJ, et al. Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the national cancer data base. J Thorac Oncol. 2015;10(2):316–323. doi:10.1097/JTO.000000000000040225319182
   PubMed Web of Science ®Google Scholar
• Roudi R, Madjd Z, Ebrahimi M, et al. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Tumour Biol. 2016;37(9):11843–11859. doi:10.1007/s13277-016-5041-y27048287
   PubMedGoogle Scholar
• zhu J, Li R, Tiselius E, et al. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2017;12(12):CD011300. doi:10.1002/14651858.CD011300.pub229247502
   PubMed Web of Science ®Google Scholar